Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Marius Rademaker; Karen Agnew; Megan Andrews; Christopher Baker; Peter Foley; Kurt Gebauer; Monisha Gupta; Diana M. Rubel; Colin Somerville; John Sullivan; Li Chuen Wong

doi:10.1111/ajd.13141

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Marius Rademaker, Karen Agnew, Megan Andrews, Christopher Baker, Peter Foley, Kurt Gebauer, Monisha Gupta, Diana M. Rubel, Colin Somerville, John Sullivan, Li Chuen Wong

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.

Original language	English
Pages (from-to)	9-22
Number of pages	14
Journal	Australasian Journal of Dermatology
Volume	61
Issue number	1
Early online date	16 Sep 2019
DOIs	https://doi.org/10.1111/ajd.13141
Publication status	Published - 1 Feb 2020

Access to Document

10.1111/ajd.13141

Cite this

@article{5b82bc368b74477e9da216b93fd7b619,

title = "Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative",

abstract = "With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.",

keywords = "atopic dermatitis, atopic eczema, azathioprine, biologic therapies, ciclosporin, corticosteroids, methotrexate, mycophenolate, second-line therapy, small molecules, systemic treatment",

author = "Marius Rademaker and Karen Agnew and Megan Andrews and Christopher Baker and Peter Foley and Kurt Gebauer and Monisha Gupta and Rubel, {Diana M.} and Colin Somerville and John Sullivan and Wong, {Li Chuen}",

year = "2020",

month = feb,

day = "1",

doi = "10.1111/ajd.13141",

language = "English",

volume = "61",

pages = "9--22",

journal = "Australian Journal of Dermatology",

issn = "0004-8380",

publisher = "John Wiley & Sons",

number = "1",

}

TY - JOUR

T1 - Managing atopic dermatitis with systemic therapies in adults and adolescents

T2 - An Australian/New Zealand narrative

AU - Rademaker, Marius

AU - Agnew, Karen

AU - Andrews, Megan

AU - Baker, Christopher

AU - Foley, Peter

AU - Gebauer, Kurt

AU - Gupta, Monisha

AU - Rubel, Diana M.

AU - Somerville, Colin

AU - Sullivan, John

AU - Wong, Li Chuen

PY - 2020/2/1

Y1 - 2020/2/1

N2 - With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.

AB - With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success.

KW - atopic dermatitis

KW - atopic eczema

KW - azathioprine

KW - biologic therapies

KW - ciclosporin

KW - corticosteroids

KW - methotrexate

KW - mycophenolate

KW - second-line therapy

KW - small molecules

KW - systemic treatment

UR - http://www.scopus.com/inward/record.url?scp=85073816351&partnerID=8YFLogxK

U2 - 10.1111/ajd.13141

DO - 10.1111/ajd.13141

M3 - Review article

C2 - 31529493

AN - SCOPUS:85073816351

VL - 61

SP - 9

EP - 22

JO - Australian Journal of Dermatology

JF - Australian Journal of Dermatology

SN - 0004-8380

IS - 1

ER -

Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative

Abstract

Access to Document

Other files and links

Fingerprint

Cite this